NCT06548815View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single-dose GZR4

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

August 29, 2022

Primary Completion Date

March 24, 2023

Study Completion Date

March 24, 2023

Conditions
Diabetes
Interventions
DRUG

GZR4

Ascending single doses - 4 dose levels.

DRUG

Placebo

Ascending single doses - 4 dose levels.

Trial Locations (1)

100000

Gan & Lee Pharmaceuticals Co., Ltd, Beijing

Sponsors
All Listed Sponsors
lead

Gan and Lee Pharmaceuticals, USA

INDUSTRY